NEW YORK (GenomeWeb News) – Sigma Life Science has reached a deal to license its CompoZr Zinc Finger Nuclease technology to Horizon Discovery on a non-exclusive basis, Sigma-Aldrich announced today.
Under the terms of the deal, Horizon will use the technology for the commercial development of cell-based products and to provide commercial gene editing services. Additional terms were not disclosed.
Horizon will apply the CompoZr technology along with its own rAAV technology in its gene editing service and cell line product business units. It will immediately begin applying the technology as part of its custom cell line generation service, Sigma said, adding that the offering will be marketed under Horizon's Genesis brand.
"Nuclease-based approaches are particularly adept at achieving rapid and efficient knock-out of two or more alleles, making them a perfect complement to Horizon's proprietary rAAV-based precision gene-editing platform," Eric Rhodes, chief technology officer of Horizon, said in a statement. "Our scientists have the expertise and now an unrivalled toolset to help guide customers toward the approach that best answers their biological question and/or suits their timescale and budget."